Harenberg J - Search Results

1

New developments in anticoagulants: Past, present and future.

Weitz JI, Harenberg J. Weitz JI, et al. Among authors: harenberg j. Thromb Haemost. 2017 Jun 28;117(7):1283-1288. doi: 10.1160/TH16-10-0807. Epub 2017 Jun 8. Thromb Haemost. 2017. PMID: 28594426 Review.

2

Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.

Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Büller HR. Harenberg J, et al. Thromb Haemost. 2000 May;83(5):652-6. Thromb Haemost. 2000. PMID: 10823256 Clinical Trial.

3

Heparin-induced thrombocytopenia: pathophysiology and new treatment options.

Harenberg J, Jörg I, Fenyvesi T. Harenberg J, et al. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):289-94. doi: 10.1159/000073583. Pathophysiol Haemost Thromb. 2002. PMID: 13679659 Free article. Review.

4

Development of new anticoagulants: present and future.

Harenberg J. Harenberg J. Semin Thromb Hemost. 2008 Nov;34(8):779-93. doi: 10.1055/s-0029-1145260. Epub 2009 Feb 12. Semin Thromb Hemost. 2008. PMID: 19214916 Review.

5

Measurement of the new anticoagulants.

Harenberg J, Kraemer R. Harenberg J, et al. Thromb Res. 2012 Apr;129 Suppl 1:S106-13. doi: 10.1016/S0049-3848(12)70028-2. Thromb Res. 2012. PMID: 22682119

6

Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C. Harenberg J, et al. Thromb Haemost. 2012 Nov;108(5):903-12. doi: 10.1160/TH12-07-0482. Epub 2012 Sep 26. Thromb Haemost. 2012. PMID: 23014668

7

Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women.

Harenberg J, Schneider D, Heilmann L, Wolf H. Harenberg J, et al. Haemostasis. 1993 Nov-Dec;23(6):314-20. doi: 10.1159/000216894. Haemostasis. 1993. PMID: 8034237 Clinical Trial.

8

Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin.

Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Harenberg J, et al. Semin Thromb Hemost. 1997;23(2):167-72. doi: 10.1055/s-2007-996086. Semin Thromb Hemost. 1997. PMID: 9200342 Clinical Trial.

9

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Gräve M, Patek F, Drexler M, Siemens HJ, Harenberg J, Weidinger G, Brom J, Haas S; TH-4 Study Group. Riess H, et al. Among authors: harenberg j. Thromb Haemost. 2003 Aug;90(2):252-9. doi: 10.1160/TH02-09-0061. Thromb Haemost. 2003. PMID: 12888872 Clinical Trial.

10

Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.

Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ; EThIG Investigators. Bauersachs RM, et al. Among authors: harenberg j. Thromb Haemost. 2007 Dec;98(6):1237-45. doi: 10.1160/th07-05-0329. Thromb Haemost. 2007. PMID: 18064320 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page